Smoke-free growth continues as U.S. ZYN stabilizes
- Philip Morris is still a tobacco company, but its smoke-free transition is advancing rapidly.
- International Smoke-Free is the main growth engine, with Q2 2026 revenue up 14.2% year over year.
- International Combustibles still brings in the most revenue and uses price increases to offset falling cigarette volumes.
- The U.S. segment showed sequential improvement in Q2 2026, with ZYN shipments returning to 2% growth.
- ZYN lawsuits have become more important after a Florida plaintiff asked the court to certify a purchaser class.
The pivot works, but faces U.S. tests
Philip Morris wants to move from cigarettes to products that do not burn tobacco. That shift is real. The strongest part of the story is outside the U.S. IQOS heated tobacco keeps gaining scale, while cigarettes still throw off cash. That gives Philip Morris money to fund the shift without walking away from its old profit pool too quickly.
The U.S. segment had a sharp drop in Q1 2026, but Q2 2026 brought a sequential rebound. ZYN shipments returned to growth. The company is now spending more money in the second half of the year to launch new ZYN Ultra flavors and defend its premium market position.
Legal risk remains a real watch item. A plaintiff in a Florida ZYN case asked the court to certify a class of people who bought ZYN in Florida. If the court allows a class, the risk could become more costly and harder to settle quietly.
Cigarette cash funds the switch
Philip Morris makes money by selling cigarettes, heated tobacco units, nicotine pouches, e-vapor products, devices, and accessories through distributors and retailers. The company owns global brands like Marlboro and smoke-free brands like IQOS and ZYN.
The model has two parts. Cigarettes are a cash cow. Volumes tend to decline over time, but premium brands can often raise prices enough to protect revenue and profit.
Smoke-free products are the growth bet. IQOS needs devices, tobacco units, approvals, and repeat use. ZYN needs shelf space, adult users, and legal permission to keep selling. If either demand or regulation breaks, the growth story weakens.
The Swedish Match deal made Philip Morris much stronger in U.S. oral nicotine. It also made the company more exposed to U.S. lawsuits and regulators tied to ZYN.
What it sells
Cigarettes
This is the old core, sold in about 170 markets. Marlboro is the flagship brand, and pricing power helps offset lower smoking volumes.
IQOS and BONDS heated tobacco
These devices heat tobacco units instead of burning them. IQOS is the center of the international smoke-free plan.
ZYN and oral nicotine
ZYN nicotine pouches came with the Swedish Match acquisition. They are a major U.S. growth product, but also the focus of lawsuits and regulatory attention.
VEEV e-vapor
VEEV is a battery device that heats a tobacco-free liquid. It gives Philip Morris another smoke-free format, though IQOS and ZYN matter more to the current thesis.
Devices and accessories
IQOS and other smoke-free systems need devices, chargers, and related accessories. These help build user habits and support repeat purchases of consumables.
New segment view
Segment mix is based on Q2 2026 net revenue under the new three-segment structure. The U.S. segment is small by revenue today, but it matters because ZYN is central to the growth debate.
What could break the story
U.S. competition hurts ZYN margins
High impact · Medium oddsZYN offtake volumes were only broadly stable to slightly growing in Q2 2026 despite improved shipments. Competitive pressures in the U.S. nicotine pouch market are intense. Philip Morris might have to cut prices or spend heavily on marketing to defend its share.
ZYN class actions gain traction
High impact · Medium oddsZYN lawsuits include claims about design, marketing to minors, and warnings about health risks. A Florida plaintiff filed a motion to certify a class of ZYN purchasers. Class certification would not decide the final case, but it could raise settlement pressure and legal exposure.
U.S. regulators limit key smoke-free products
High impact · Medium oddsPhilip Morris needs U.S. regulatory clearance to grow IQOS ILUMA and must keep ZYN within rules for nicotine products. Prior attention from the D.C. Attorney General showed that sales practices can become a direct business issue. A setback could slow the U.S. growth plan.
Cigarette pricing stops covering volume declines
Medium impact · Medium oddsInternational Combustibles is still the largest segment. Its revenue grew year over year in Q2 2026 as pricing offset lower volumes. If price increases stop working, the cash engine that funds the smoke-free shift could weaken.
In one breath
Is Philip Morris still mainly a cigarette company?
Cigarettes are still the largest segment by revenue through International Combustibles. But the company is far into its transition, with smoke-free products generating over 40% of revenue.
Why does ZYN matter so much to Philip Morris?
ZYN is the company’s key U.S. oral nicotine product after the Swedish Match acquisition. It can grow without cigarette smoke, but it also brings U.S. legal and regulatory risk.
What is the main thing to watch next?
The next key test is whether the U.S. segment growth accelerates after increased marketing investments in late 2026. Investors should also watch court rulings on ZYN class certification and FDA decisions for IQOS ILUMA.
